SCHEMBL100651

SCHEMBL100651

Clc1ccnc2[nH]ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 5/20 1.00
AXL P30530 2/20 1.00
DYRK1B Q9Y463 3/20 0.52
JAK2 O60674 2/20 0.52
AURKB Q96GD4 2/20 0.52
IGF1R P08069 2/20 0.52
IKBKB O14920 1/20 0.52
CHUK O15111 1/20 0.52
DAPK3 O43293 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PAK4 O96013 1/20 0.52
CSF1R P07333 1/20 0.52
RET P07949 1/20 0.52
FGFR1 P11362 1/20 0.52
PRKACA P17612 1/20 0.52
FLT1 P17948 1/20 0.52
LTK P29376 1/20 0.52
GRK5 P34947 1/20 0.52
KDR P35968 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29431037 1.00 PRKCI (1.00) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL28757490 0.91 PRKCI (0.82) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL11889555 0.85 PRKCI (0.72) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL2240671 0.77 AURKB (0.71) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL12613153 0.76 PRKCI (0.61) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL4793014 0.76 IGF1R (0.63) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL12127566 0.76 NUDT1 (0.61) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL858771 0.74 PRKCI (0.59) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL21062776 0.74 PRKCI (0.59) PRKCIAXLDYRK1BJAK2AURKB
SCHEMBL1176829 0.74 PRKCI (0.59) PRKCIAXLDYRK1BJAK2AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1888 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117304068-A Preparation method for synthesizing 2, 2-diisopropyl propionitrile from 2, 3-dimethylbutyramide 濮阳天源生物科技有限公司 2023-12-29 CN claimed
CN-112867716-A Solid forms of FGFR inhibitors and methods for their preparation 因赛特公司 2021-05-28 CN claimed
CN-213229675-U Reagent storage device for preparing 4-chloro-7-azaindole 南通雅本化学有限公司 2021-05-18 CN claimed
CN-212720612-U Drying device is used in production of 4-chlorine-7-azaindole 南通雅本化学有限公司 2021-03-16 CN claimed
EP-3788047-A2 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME Incyte Corporation (US) 2021-03-10 EP claimed
CN-111499676-A 4-chloro-3-nitro-1-p-toluenesulfonyl-7-azaindole derivative and preparation method and application thereof 绍兴文理学院 2020-08-07 CN claimed
US-20190337948-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME WILMINGTON PHARMATECH 2019-11-07 US claimed
EP-2855473-B1 PROCESS FOR PREPARING INTERMEDIATES COMPOUND GENENTECH INC (US) 2018-10-03 EP claimed
CN-105777747-A 4-chloro-7-azaindole and preparation method thereof 叶芳 2016-07-20 CN claimed
US-9221813-B2 Intermediates and processes for preparing compounds GENENTECH, INC. (US) 2015-12-29 US claimed
US-20150105557-A1 INTERMEDIATES AND PROCESSES FOR PREPARING COMPOUNDS GENENTECH, INC. 2015-04-16 US claimed
EP-2855473-A1 INTERMEDIATES AND PROCESSES FOR PREPARING COMPOUNDS Genentech, Inc. (US) 2015-04-08 EP claimed
WO-2013163109-A1 INTERMEDIATES AND PROCESSES FOR PREPARING COMPOUNDS GENENTECH, INC. (US) 2013-10-31 WO claimed
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 EP disclosed
CN-116496219-B Six-membered and five-membered heterocyclic compound, and pharmaceutical composition and application thereof 东南大学 2026-05-15 CN disclosed
US-20260125379-A1 PRODRUG OF JAK KINASE INHIBITOR E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) 2026-05-07 US disclosed
EP-1218348-A2 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2002-07-03 EP disclosed
WO-2002012240-A1 DERIVATIVES OF VARIOLIN B UNIVERSIDAD DE BARCELONA (ES) 2002-02-14 WO disclosed
WO-2001046196-A1 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-06-28 WO disclosed
WO-2001002369-A2 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105557-A1 INTERMEDIATES AND PROCESSES FOR PREPARING COMPOUNDS CHEK1, CHEK2, PLK1 PRKCI 201/4885AXL 1353/4885DYRK1B 2168/4885
US-20190337948-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME FGFR1, FGFR2, FGFR3 PRKCI 718/4885AXL 15/4885DYRK1B 178/4885
US-20260125379-A1 PRODRUG OF JAK KINASE INHIBITOR JAK1, JAK2, JAK3 PRKCI 286/4885AXL 103/4885DYRK1B 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.